Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 23, 2006
- Accepted for publication July 25, 2006
- Published online October 2, 2006.
Copyright & Usage
© 2006 by Society of Nuclear Medicine
Author Information
- Martijn van Essen 1 ,
- Eric P. Krenning 1 , 2 ,
- Peter P. Kooij 1 ,
- Willem H. Bakker 1 ,
- Richard A. Feelders 2 ,
- Wouter W. de Herder 2 ,
- John G. Wolbers 3 and
- Dik J. Kwekkeboom 1
- 1Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 2Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and 3Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
- For correspondence or reprints contact: Martijn van Essen, MD, Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. E-mail: m.vanessen{at}erasmusmc.nl
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up
- DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas
- Metastatic paraganglioma presenting with spinal cord compression requiring urgent surgery
- Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
- Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
- Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
- Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
- 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma
- THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
- The management of head-and-neck paragangliomas
- Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas
- 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas